22:56 , Apr 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies identified p53-activating tetrahydroindazole-based DHODH inhibitors that could help treat melanoma. Screening of a small molecule library in human melanoma cell line-based assays of p53-dependent transcription, followed by chemical...
19:50 , Aug 18, 2017 |  BC Week In Review  |  Company News

Aslan and Academia Sinica combine ASLAN003 and varlitinib in animal models

Aslan Pharmaceuticals Ltd. (TPEx:6497) and Academia Sinica (Taipei, Taiwan) partnered to evaluate the the combination of varlitinib ( ASLAN001 ) and ASLAN003 in animal models for gastric, colorectal and lung cancers. The partners said the...
19:57 , Mar 10, 2017 |  BC Week In Review  |  Company News

Aslan, CSI, NCIS deal

Aslan, CSI and NCIS partnered to develop ASLAN003 to treat hematologic cancers as monotherapy and in combination with other undisclosed agents. Aslan is developing the oral dihydroorotate dehydrogenase (DHODH) inhibitor to treat cancer, including acute...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Company News

Almirall, Aslan deal

Aslan and Almirall expanded a 2012 deal to grant Aslan exclusive, worldwide rights to develop and commercialize ASLAN003 ( LAS186323 ) for all non-topical and non-dermatological indications, including cancer. The small molecule oral dihydroorotate dehydrogenase...
07:00 , Apr 29, 2013 |  BC Week In Review  |  Clinical News

ASLAN003: Phase I start

Next month, Aslan will begin a double-blind, placebo-controlled, Singaporean Phase I trial to evaluate multiple ascending-doses of ASLAN003 in healthy volunteers. Last May, Almirall granted Aslan exclusive, worldwide rights to the compound. Aslan will conduct...
07:00 , May 28, 2012 |  BC Week In Review  |  Company News

Almirall, Aslan deal

Almirall granted Aslan exclusive, worldwide rights to develop LAS186323 , a dihydroorotate dehydrogenase (DHODH) inhibitor in Phase I testing for rheumatoid arthritis. Aslan will conduct and fund development through the end of Phase II trials,...
23:34 , May 21, 2012 |  BC Extra  |  Company News

Almirall out-licenses RA compound to Aslan

Almirall S.A. (Madrid:ALM) granted Aslan Pharmaceuticals Pte. Ltd. (Singapore) worldwide rights to develop LAS186323 , a dihydroorotate dehydrogenase (DHODH) inhibitor in Phase I testing for rheumatoid arthritis. Aslan will conduct and fund development through the...
07:00 , Apr 7, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Melanoma Dihydroorotate dehydrogenase (DHODH) In vitro and mouse studies suggest that DHODH inhibitors used in combination with BRAF inhibitors could help treat melanoma. In...
07:00 , Mar 31, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Viral infection Dihydroorotate dehydrogenase (DHODH) In vitro studies suggest that DHODH inhibitors could help treat a variety of viral infections....